van den Ancker W - Search Results

1

Procedures for the expansion of CD14(+) precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy.

van den Ancker W, Wijnands PG, Ruben JM, Westers TM, Punt B, Bachas C, Ravenshorst N, van Wetering S, Kruisbeek AM, Bontkes HJ, Ossenkoppele GJ, van de Loosdrecht AA, de Gruijl TD. van den Ancker W, et al. Immunotherapy. 2013 Nov;5(11):1183-90. doi: 10.2217/imt.13.125. Immunotherapy. 2013. PMID: 24188673 Clinical Trial.

2

Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.

van de Loosdrecht AA, van den Ancker W, Houtenbos I, Ossenkoppele GJ, Westers TM. van de Loosdrecht AA, et al. Among authors: van den ancker w. Handb Exp Pharmacol. 2009;(188):319-48. doi: 10.1007/978-3-540-71029-5_15. Handb Exp Pharmacol. 2009. PMID: 19031033 Review.

3

Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia.

van Luijn MM, van den Ancker W, Chamuleau ME, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA. van Luijn MM, et al. Among authors: van den ancker w, van ham sm, van de loosdrecht aa. Immunotherapy. 2010 Jan;2(1):85-97. doi: 10.2217/imt.09.84. Immunotherapy. 2010. PMID: 20635891 Review.

4

Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.

van den Ancker W, van Luijn MM, Westers TM, Bontkes HJ, Ruben JM, de Gruijl TD, Ossenkoppele GJ, van de Loosdrecht AA. van den Ancker W, et al. Among authors: van luijn mm, van de loosdrecht aa. Immunotherapy. 2010 Jan;2(1):69-83. doi: 10.2217/imt.09.85. Immunotherapy. 2010. PMID: 20635890 Review.

5

Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation.

van den Ancker W, van Luijn MM, Ruben JM, Westers TM, Bontkes HJ, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA. van den Ancker W, et al. Among authors: van luijn mm, van de loosdrecht aa. Cancer Immunol Immunother. 2011 Jan;60(1):37-47. doi: 10.1007/s00262-010-0917-y. Epub 2010 Sep 22. Cancer Immunol Immunother. 2011. PMID: 20859626 Free PMC article.

6

Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.

van Luijn MM, van den Ancker W, Chamuleau ME, Zevenbergen A, Westers TM, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA. van Luijn MM, et al. Among authors: van den ancker w, van ham sm, van de loosdrecht aa. Cancer Res. 2011 Apr 1;71(7):2507-17. doi: 10.1158/0008-5472.CAN-10-3689. Epub 2011 Feb 10. Cancer Res. 2011. PMID: 21310823 Free article.

7

Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells.

Westers TM, van den Ancker W, Bontkes HJ, Janssen JJ, van de Loosdrecht AA, Ossenkoppele GJ. Westers TM, et al. Among authors: van den ancker w. Immunotherapy. 2011 Apr;3(4):569-76. doi: 10.2217/imt.11.3. Immunotherapy. 2011. PMID: 21463196

8

MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemia.

de Leeuw DC, van den Ancker W, Denkers F, de Menezes RX, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA, Smit L. de Leeuw DC, et al. Among authors: van den ancker w. Clin Cancer Res. 2013 Apr 15;19(8):2187-96. doi: 10.1158/1078-0432.CCR-12-3657. Epub 2013 Feb 26. Clin Cancer Res. 2013. PMID: 23444217

9

Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines.

Ruben JM, van den Ancker W, Bontkes HJ, Westers TM, Hooijberg E, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA. Ruben JM, et al. Among authors: van den ancker w. Cancer Immunol Immunother. 2014 Apr;63(4):335-45. doi: 10.1007/s00262-013-1515-6. Epub 2014 Jan 3. Cancer Immunol Immunother. 2014. PMID: 24384837 Free PMC article.

10

High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.

van den Ancker W, van Luijn MM, Chamuleau ME, Kelder A, Feller N, Terwijn M, Zevenbergen A, Schuurhuis GJ, van Ham SM, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. van den Ancker W, et al. Leuk Res. 2014 Jun;38(6):691-3. doi: 10.1016/j.leukres.2014.03.014. Epub 2014 Mar 25. Leuk Res. 2014. PMID: 24731748

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters